Ts03 Inc (TSTIF) 2.5314 $TSTIF TSO3 Receives U.S.

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Ts03 Inc (TSTIF) 2.5314 $TSTIF

TSO3 Receives U.S. Clearance for Extended Claims for Its Breakthrough Medical Device Sterilizer
PR Newswire - Mon Jul 04, 6:30AM CDT
Double and Multiple-Channel Endoscopes (with No More than Four Channels) Among Devices Cleared for Use in TSO3's STERIZONE® VP4 Sterilizer - an Industry First
TOS.TO: 3.29 (-0.08)

TSO3 Responds to U.S. Regulators on Extended Claims and Provides Operations Update
PR Newswire - Wed Jun 01, 4:00PM CDT
TSO3 Inc. (TSX: TOS), an innovator in sterilization technology for medical devices in healthcare settings, announced today that it has responded to a previously announced request for additional information by the U.S. Food and Drug Administration (the FDA) and that it has substantially completed its improvements to its manufacturing facility in Québec.
TOS.TO: 3.29 (-0.08)

Canadian Journal of Infection Control to Publish Paper on TSO3's STERIZONE® VP4 Sterilizer
PR Newswire - Wed May 18, 1:36PM CDT
TSO3 Inc. (TSX: TOS), an innovator in sterilization technology for medical devices in healthcare settings, announced today that a peer-reviewed paper describing the Company's STERIZONE® VP4 Sterilizer has been accepted for publication in the Canadian Journal of Infection Control (CJIC). The paper entitled "The First Dual-Sterilant Low-Temperature Sterilization System" will appear in an upcoming issue of the publication.
TOS.TO: 3.29 (-0.08)

TSO3 announces the Results of the Votes from its Annual and Special Meeting of the Shareholders
PR Newswire - Thu May 05, 3:02PM CDT
TSO3 Inc. (TSX: TOS), an innovator in sterilization technology for medical devices in healthcare settings, today announced that the nominees listed in the management proxy circular dated March 22, 2016, were elected as directors of TSO3 Inc. In addition, all other proposals submitted by management were approved.
TOS.TO: 3.29 (-0.08)

TSO3 Reports Record First Quarter 2016 Results
PR Newswire - Wed May 04, 5:30AM CDT
Commercial Rollout Drives Revenues of US$3.1 Million and Gross Profit of US$1.1 Million
TOS.TO: 3.29 (-0.08)

TSO3 to Report First Quarter 2016 Results and Hold Annual General and Special Meeting of Shareholders on Wednesday, May 4, 2016
PR Newswire - Tue Apr 26, 6:30AM CDT
TSO3 Inc. (TSX: TOS), an innovator in sterilization technology for medical devices in healthcare settings, will report its first quarter 2016 financial results ended March 31, 2016 via press release on Wednesday, May 4, 2016 before the market opens.
TOS.TO: 3.29 (-0.08)

TSO3 to Present at Bloom Burton & Co. Healthcare Investor Conference on May 2, 2016
PR Newswire - Mon Apr 18, 6:30AM CDT
TSO3 Inc. (TSX: TOS), an innovator in sterilization technology for medical devices in healthcare settings, has been invited to present at Bloom Burton & Co. Healthcare Investor Conference being held on May 2-3, 2016 at the Sheraton Centre Toronto Hotel in Toronto, Ontario.
TOS.TO: 3.29 (-0.08)

TSO3 Receives FDA 510(k) Clearance for Universal Design of STERIZONE® VP4 Sterilizer
PR Newswire - Mon Mar 28, 6:00AM CDT
TSO3 Inc. (TSX: TOS), an innovator in sterilization technology for medical devices in healthcare settings, has received FDA 510(k) clearance from the U.S. Food and Drug Administration (FDA) for a universal design of its STERIZONE® VP4 Sterilizer.
TOS.TO: 3.29 (-0.08)

TSO3 Reports Fourth Quarter and Full Year 2015 Results
PR Newswire - Wed Mar 23, 6:00AM CDT
Orders Received in 2015 Drive 2016 Commercial Rollout of STERIZONE® VP4 Sterilizer
TOS.TO: 3.29 (-0.08)

TSO3 Provides Update on Extended U.S. Claims Filed for Breakthrough Medical Device Sterilizer
PR Newswire - Mon Mar 14, 6:00AM CDT
TSO3 Inc. (TSX: TOS), an innovator in sterilization technology for medical devices in healthcare settings, has received feedback from the U.S. regulators regarding the company's recent application to extend claims for the STERIZONE® VP4 Sterilizer.
TOS.TO: 3.29 (-0.08)

TSO3 to Present at the 28th Annual ROTH Conference on March 16, 2016
PR Newswire - Thu Mar 10, 6:30AM CST
TSO3 Inc. (TSX: TOS), an innovator in sterilization technology for medical devices in healthcare settings, has been invited to present at the 28th Annual ROTH Capital Partners Conference, which is being held on March 14-16, 2016 at The Ritz-Carlton, Laguna Niguel in Dana Point, California.
TOS.TO: 3.29 (-0.08)

TSO3 Appoints Harold R. Tessman as COO
PR Newswire - Wed Jan 27, 5:30AM CST
TSO3 Inc. (TSX: TOS), a leader in low-temperature medical device sterilization, has appointed Harold R. Tessman to the new position of chief operating officer.
TOS.TO: 3.29 (-0.08)

TSO3 Completes Additional Studies, Files Extended U.S. Claims for Breakthrough Medical Device Sterilizer
PR Newswire - Tue Dec 22, 6:00AM CST
Company Submits Required Documentation Seeking Clearance to Extend Sterilization Claims to Include up to Eight Channels in a Single Device for its STERIZONE® VP4 Sterilizer - an Industry First
TOS.TO: 3.29 (-0.08)

TSO3 to Expand Manufacturing Workforce to Meet Demand for STERIZONE® VP4 Sterilizer
PR Newswire - Mon Dec 21, 3:37PM CST
Company Notifies Suppliers and Accelerates Workforce Recruitment in Canada and the United States
TOS.TO: 3.29 (-0.08)

TSO3 Appoints Glen Kayll as Chief Financial Officer
PR Newswire - Fri Dec 18, 6:00AM CST
Seasoned Public Company CFO With Financial and Cross Border Listing Experience to Join Management Team
TOS.TO: 3.29 (-0.08)

TSO3 Establishes Medical Industry's First-Ever Claims for Duodenoscope Terminal Sterilization
PR Newswire - Thu Dec 17, 6:00AM CST
STERIZONE® VP4 Sterilizer Validated to Sterilize Complex, Multi-Channel Endoscopic Devices
TOS.TO: 3.29 (-0.08)

TSO3 and GETINGE Infection Control Sign Exclusive Global Distribution Agreement
PR Newswire - Wed Nov 25, 10:40AM CST
US$7.5 Million Up-Front License Fees and Performance Minimums Highlights of Agreement
TOS.TO: 3.29 (-0.08)

IIROC Trade Halt - TSO3 Inc.
Newsfile Corp - Wed Nov 25, 8:36AM CST
The following issues have been halted by IIROC:

TSO3 Appoints Steve West to Board of Directors
PR Newswire - Tue Nov 10, 9:14AM CST
TSO3 Inc. (TSX: TOS), an innovator in sterilization technology for medical devices in healthcare settings, has appointed Steve West to the Company's board of directors.
TOS.TO: 3.29 (-0.08)

TSO3 Reports Third Quarter 2015 Financial Results
PR Newswire - Wed Nov 04, 6:00AM CST
Q3 Revenues Ramp to $1.2 Million, Driven by U.S. Commercial Rollout of STERIZONE® VP4 Sterilizer Build-Out of U.S. Distribution and Customer Support Facility Complete
TOS.TO: 3.29 (-0.08)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study

Updated Category News Views 145

Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...

Continue Reading
Love Business Group Helps SMEs Navigate Broadband Choices

Updated Category News Views 17

Understanding Broadband Needs for UK SMEs When you're knee-deep in running a small biz in the UK, sorting out your broadband needs can feel like sifting through a thousand-piece puzzle. Enter Love Business Group, getting a nod of recognition for being the SME knight in shining armor. Aimed at businesses of all sizes, they've been pegged by Expert Consumers for helping...

Continue Reading
Sac-TMT's Phase III Success Shifts Lung Cancer Paradigm

Updated Category News Views 311

A New Era in Lung Cancer Treatment? Sac-TMT, the novel antibody-drug conjugate (ADC), just might be shaking up the non-small cell lung cancer (NSCLC) treatment landscape, and boy, is it making waves. Just when you think you’ve seen it all, here comes sacituzumab tirumotecan (sac-TMT), offering a glimmer of hope for patients whose treatment options have dwindled after...

Continue Reading
ASTS Faces Crucial Deadline Amidst Legal Turmoil

Updated Category News Views 208

Ah, the ticking clock in the world of stock investments, where a nifty little thing called a class action lawsuit can flip your investment on its head. Right now, AST SpaceMobile (NASDAQ: ASTS) investors are staring down the barrel of one such lawsuit. With the November 13, 2026, deadline looming, it's time to sort the facts from the muck. Pins and Needles for ASTS...

Continue Reading
RYBREVANT's Promising Results in HNSCC Treatment

Updated Category News Views 35

Impressive Outcomes for RYBREVANT FASPRO in Head and Neck Cancer Tucked away in the endless cycle of drug trials, a glimmer of hope shines through with new data on RYBREVANT FASPRO in treating head and neck squamous cell carcinoma (HNSCC). This science talk might not rattle the ticker tape directly on NYSE:JNJ, but it has all the makings of a game-changer in the oncology...

Continue Reading
Firefox Champions Privacy with Iconic Internet Campaign

Updated Category News Views 68

Rekindling the Internet’s Golden Days with Firefox There’s something almost poetic about Firefox hustling to win back its old users by launching a campaign with legendary internet icons. The backdrop? A digital landscape where privacy feels about as common as a unicorn sighting. Mozilla's pulling a major nostalgia card, and I'm here for it—sort of like how vinyl...

Continue Reading
Innovent's IBI354: New Data Spurs Hope for HER2+ BC

Updated Category News Views 106

Innovent Lauds HER2 ADC's Moment at ESMO 2026 Alright, chin up, investors. At the 2026 ESMO Congress, Innovent's throwing down some promising Phase 2 data for their brainchild, IBI354. You hear that name and it's like hearing about a rock star in the making in the oncology world. The potential here isn’t just talk—it's a loud, resounding call for attention. Their...

Continue Reading
Kelun-Biotech's Sacituzumab Tirumotecan Shows Promise in NSCLC

Updated Category News Views 147

Kelun-Biotech's Recent Breakthrough Grab your coffee, and let's chat about something that might just change the lung cancer treatment game: Kelun-Biotech's sacituzumab tirumotecan, or sac-TMT, showing some serious promise in a Phase III trial. With numbers that could make any investor sit up a little straighter, this study has turned heads at the European Society for...

Continue Reading
Gildan Activewear Faces Legal Battle Over Alleged Fraud

Updated Category News Views 0

Investor Alert: Gildan's Legal Showdown Alright, here's a twist you didn't see coming—or maybe you did if you've been tracking the ticker tapes like a hawk. Gildan Activewear Inc. (NYSE:GIL) is stuck in the kind of hot water that can scald the bottom line. The Stakes: Racing Towards December 14 Marked on your calendar, December 14, is a date of some significance if...

Continue Reading
TORRAS Cases Balance Protection with Slim Design for 2026

Updated Category News Views 113

Are Slim iPhone Cases Really Protecting Your Investment? Anyone who's dropped a brand-new phone knows the pain of watching your investment smack the concrete. But hey, welcome to 2026, where Consumer365's latest rundown on iPhone protective gear turns the spotlight on TORRAS. These folks grabbed attention with their Q3 Air and Q3 Air Pro cases, crafted for iPhone 18 Pro...

Continue Reading

Top 5 Most Recently Viewed Articles

Understanding Preeclampsia: Key Insights for Expecting Parents

Updated Category News Views 46

Preeclampsia: Essential Insights for Expecting Parents Preeclampsia is a significant condition that often raises concerns among expecting parents. It manifests as a dangerous form of high blood pressure during pregnancy and can also surface postpartum. Understanding this condition is vital for ensuring the health and safety of both mother and child during this crucial...

Continue Reading
DTE Energy Enhances Reliability with Smart Grid Technology

Updated Category News Views 240

DTE Energy's Progress with Smart Grid Technology DTE Energy (NYSE:DTE) has announced impressive strides in enhancing energy reliability through its cutting-edge smart grid technology. This initiative has successfully prevented nearly 5,000 power interruptions and saved over 1.8 million outage minutes for customers this year, highlighting the technology's role in ensuring...

Continue Reading
Key Insider Transactions in Major US Companies Unveiled

Updated Category News Views 270

Significant Insider Trading Activities This article sheds light on the notable insider buying and selling events reported recently, reflecting the movements within major US stocks. Major Insider Purchases Berkshire Hathaway Inc. (NYSE: BRKa) has made headlines by increasing its stake in Verisign Inc. (NASDAQ: VRSN). Under the leadership of Warren E. Buffett, the company...

Continue Reading
Hull Tactical's Latest Research Paper Enhances Market Predictions

Updated Category News Views 135

Hull Tactical Releases Innovative Academic Research The Hull Tactical team is excited to unveil its latest academic paper, titled Micro Alphas, co-authored by a talented group including Blair Hull, Petra Bakosova, Francois Cocquemas, Euan Sinclair, and Petri Fast. This research introduces a fresh framework that focuses on utilizing weak yet collectively informative...

Continue Reading
Cyrano Therapeutics and KYORIN Join Forces for Smell Loss Treatment

Updated Category News Views 138

Cyrano Therapeutics and KYORIN Collaboration Overview Cyrano Therapeutics, a pioneer in regenerative medicine, has taken a significant step forward in addressing the challenge of post-viral loss of smell. The company has entered into an option agreement with KYORIN Pharmaceutical Co., Ltd. to develop CYR-064, a promising treatment candidate specifically designed for those...

Continue Reading